Orgovyx Tablet, Film Coated
Product Images NDC 72974-120

6 FDA label images from Sumitomo Pharma America, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Orgovyx (NDC 72974-120). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sumitomo Pharma America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Org01 0003 01)

Structural Formula (Org01 0003 01)
Chemical structure of relugolix, the active ingredient in Orgovyx. The diagram depicts the molecular arrangement of atoms and bonds characteristic of relugolix.*
FDA Label Image

Figure 1 (Org01 0003 02)

Figure 1 (Org01 0003 02)
A line graph depicting changes in follicle-stimulating hormone (FSH) and luteinizing hormone (LH) concentrations over a 49-week period and safety follow-up for a group treated with relugolix. The graphs show measurements at baseline, week 5, week 25, week 49, and safety follow-up, with hormone levels largely stable until a rise at safety follow-up after end of treatment.*
FDA Label Image

Figure 2 (Org01 0003 03)

Figure 2 (Org01 0003 03)
A line graph comparing mean percent change in testosterone levels from baseline over 49 weeks for Relugolix and Leuprolide. The y-axis represents percent change in testosterone, and the x-axis shows time in weeks. Data points for both treatments are plotted, showing a rapid decrease to near baseline levels. The chart includes a legend identifying each treatment and the number of evaluable patients at each time point.*
FDA Label Image

Figure 3 (Org01 0003 04)

Figure 3 (Org01 0003 04)
A chart showing the cumulative incidence of time to testosterone levels below 50 ng/dL over weeks, comparing relugolix and leuprolide. The x-axis represents time in weeks, and the y-axis shows the cumulative incidence percentage. The graph illustrates the time course for achieving low testosterone with each treatment.*
FDA Label Image

Figure 3 (Org01 0003 05)

Figure 3 (Org01 0003 05)
A cumulative incidence graph depicting time to testosterone levels dropping below 20 ng/dL, comparing relugolix treatment to a leuprolide reference. The x-axis shows time in weeks, and the y-axis shows cumulative incidence proportion over 1.0. Two curves are displayed representing the two treatments over approximately 5 weeks.*
FDA Label Image

Principal Display Panel (120 mg Tablet Bottle Label)

Principal Display Panel (120 mg Tablet Bottle Label)
Label for Orgovyx (relugolix) tablets, 120 mg strength, oral film-coated tablets. The label shows the product name, strength, quantity of 30 tablets, and the NDC 72974-120-01. It includes manufacturer information for Sumitomo Pharma America, Inc., Marlborough, MA, and storage instructions to keep the product at room temperature below 30°C (86°F).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.